Myelodysplastic Syndrome Splicing Factor Mutations Induce R-Loops.

Abstract:

:Mutations in SRSF2 and U2AF35 trigger replication stress and ATR activation via R-loop formation.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

doi

10.1158/2159-8290.CD-RW2018-025

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

OF13

issue

4

eissn

2159-8274

issn

2159-8290

pii

2159-8290.CD-RW2018-025

journal_volume

8

pub_type

评论,新闻
  • New FDA Center May Speed Approval Process.

    abstract::The FDA's new Oncology Center of Excellence is aimed at consolidating the approval processes for new cancer drugs, biologics, and devices. Richard Pazdur, MD, current director of the agency's Office of Hematology and Oncology Products within the Center for Drug Evaluation and Research will serve as the new center's ac...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2016-092

    authors:

    更新日期:2016-09-01 00:00:00

  • Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

    abstract::Targeting the dysregulated BRAF-MEK-ERK pathway in cancer has increasingly emerged in clinical trial design. Despite clinical responses in specific cancers using inhibitors targeting BRAF and MEK, resistance develops often involving nongenomic adaptive bypass mechanisms. Inhibition of MEK1/2 by trametinib in patients ...

    journal_title:Cancer discovery

    pub_type: 临床试验,杂志文章

    doi:10.1158/2159-8290.CD-16-0653

    authors: Zawistowski JS,Bevill SM,Goulet DR,Stuhlmiller TJ,Beltran AS,Olivares-Quintero JF,Singh D,Sciaky N,Parker JS,Rashid NU,Chen X,Duncan JS,Whittle MC,Angus SP,Velarde SH,Golitz BT,He X,Santos C,Darr DB,Gallagher K,Gr

    更新日期:2017-03-01 00:00:00

  • Targeting HDAC And PI3K Inhibits MYC-Driven Medulloblastoma Growth.

    abstract::HDAC inhibitors synergize with PI3K inhibitors to reduce MYC-driven medulloblastoma (MB) growth. ...

    journal_title:Cancer discovery

    pub_type: 评论,信件

    doi:10.1158/2159-8290.CD-RW2016-052

    authors:

    更新日期:2016-05-01 00:00:00

  • LXR agonism inhibits metastatic melanoma through activation of ApoE.

    abstract::Nuclear hormone receptor targeting suppresses melanoma progression in diverse preclinical models. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2014-056

    authors:

    更新日期:2014-05-01 00:00:00

  • The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

    abstract::To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-19-0125

    authors: Nechiporuk T,Kurtz SE,Nikolova O,Liu T,Jones CL,D'Alessandro A,Culp-Hill R,d'Almeida A,Joshi SK,Rosenberg M,Tognon CE,Danilov AV,Druker BJ,Chang BH,McWeeney SK,Tyner JW

    更新日期:2019-07-01 00:00:00

  • Mitochondrial Oxidation of Ubiquinol Is Required for Tumorigenesis.

    abstract::The ability of mitochondrial complex III to oxidize ubiquinol was essential to tumor growth in vivo. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2020-107

    authors:

    更新日期:2020-09-01 00:00:00

  • Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations.

    abstract:UNLABELLED:Pancreatic ductal adenocarcinoma is refractory to available therapies. We have previously shown that these tumors have elevated autophagy and that inhibition of autophagy leads to decreased tumor growth. Using an autochthonous model of pancreatic cancer driven by oncogenic Kras and the stochastic LOH of Trp5...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-14-0362

    authors: Yang A,Rajeshkumar NV,Wang X,Yabuuchi S,Alexander BM,Chu GC,Von Hoff DD,Maitra A,Kimmelman AC

    更新日期:2014-08-01 00:00:00

  • Stabilization of a closed kinase conformation induces RAF dimerization.

    abstract::BRAF inhibitors stabilize a closed, rigid RAF kinase conformation that facilitates dimerization. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2013-114

    authors:

    更新日期:2013-07-01 00:00:00

  • Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer.

    abstract::Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease. Because of its heterogeneity and lack of hormone receptors or HER2 expression, targeted therapy is limited. Here, by performing a functional siRNA screening for 2-OG-dependent enzymes, we identified gamma-butyrobetaine hydroxylase 1 (BBOX...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-20-0288

    authors: Liao C,Zhang Y,Fan C,Herring LE,Liu J,Locasale JW,Takada M,Zhou J,Zurlo G,Hu L,Simon JM,Ptacek TS,Andrianov VG,Loza E,Peng Y,Yang H,Perou CM,Zhang Q

    更新日期:2020-11-01 00:00:00

  • EZH2 Inhibitors: Take It EZy, It Is All About Context.

    abstract::Even in diffuse large B-cell lymphoma (DLBCL), a cancer of professional antigen-presenting cells, response rates to immune checkpoint blockade therapy have been limited. One reason for DLBCL immune evasion is epigenetic repression instead of activation of the antigen-presenting MHC-a dissection of mechanisms underlyin...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-19-0090

    authors: Velcheti V,Wong KK,Saunthararajah Y

    更新日期:2019-04-01 00:00:00

  • Pembrolizumab Approved for Hodgkin Lymphoma.

    abstract::The FDA has approved pembrolizumab for adults and children with classical Hodgkin lymphoma whose disease is refractory to or has relapsed after at least three prior therapies. The approval marks the first time that a PD-1 inhibitor has been indicated for blood cancers-and for children. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-044

    authors:

    更新日期:2017-05-01 00:00:00

  • Metabolic Codependencies in the Tumor Microenvironment.

    abstract::Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This reprogramming is driven by the combined actions of oncogenic alterations in cancer cells and host cell factors acting on cancer cells in the tumor microenvironment. Cancer cell intrinsic mechanisms activate signal transduction compon...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-20-1211

    authors: Dey P,Kimmelman AC,DePinho RA

    更新日期:2021-01-27 00:00:00

  • Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.

    abstract:UNLABELLED:CD96 has recently been shown as a negative regulator of mouse natural killer (NK)-cell activity, with Cd96(-/-)mice displaying hyperresponsive NK cells upon immune challenge. In this study, we have demonstrated that blocking CD96 with a monoclonal antibody inhibited experimental metastases in three different...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-15-0944

    authors: Blake SJ,Stannard K,Liu J,Allen S,Yong MC,Mittal D,Aguilera AR,Miles JJ,Lutzky VP,de Andrade LF,Martinet L,Colonna M,Takeda K,Kühnel F,Gurlevik E,Bernhardt G,Teng MW,Smyth MJ

    更新日期:2016-04-01 00:00:00

  • Forty years of translational cancer research.

    abstract::Forty years after the signing of the National Cancer Act, we have produced a stunning repository of scientific information that is being translated into better therapies for patients. Although challenges remain, many solutions have been adopted, leading to early signs of progress against some of humankind's most dread...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0196

    authors: Hait WN

    更新日期:2011-10-01 00:00:00

  • Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.

    abstract::Epigenetic regulators, when genomically altered, may become driver oncogenes that mediate otherwise unexplained pro-oncogenic changes lacking a clear genetic stimulus, such as activation of the WNT/β-catenin pathway in melanoma. This study identifies previously unrecognized recurrent activating mutations in the G9a hi...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-19-0532

    authors: Kato S,Weng QY,Insco ML,Chen KY,Muralidhar S,Pozniak J,Diaz JMS,Drier Y,Nguyen N,Lo JA,van Rooijen E,Kemeny LV,Zhan Y,Feng Y,Silkworth W,Powell CT,Liau BB,Xiong Y,Jin J,Newton-Bishop J,Zon LI,Bernstein BE,Fish

    更新日期:2020-07-01 00:00:00

  • Patient-derived xenograft models: an emerging platform for translational cancer research.

    abstract:UNLABELLED:Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have ...

    journal_title:Cancer discovery

    pub_type: 杂志文章,评审

    doi:10.1158/2159-8290.CD-14-0001

    authors: Hidalgo M,Amant F,Biankin AV,Budinská E,Byrne AT,Caldas C,Clarke RB,de Jong S,Jonkers J,Mælandsmo GM,Roman-Roman S,Seoane J,Trusolino L,Villanueva A

    更新日期:2014-09-01 00:00:00

  • Desmoid Tumors Respond to Sorafenib.

    abstract::A recent clinical trial shows that sorafenib is effective against desmoid tumors. The study found that 33% of tumors shrank in patients who received the drug. The estimated 1-year progression-free survival for the sorafenib-treated patients was 89%, and the 2-year rate was 81%. ...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-NB2019-004

    authors:

    更新日期:2019-03-01 00:00:00

  • First Comprehensive Companion Diagnostic OK'd.

    abstract::The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-182

    authors:

    更新日期:2018-03-01 00:00:00

  • Nod for Atezolizumab in Advanced Bladder Cancer.

    abstract::The FDA approved atezolizumab to treat advanced bladder cancer when cisplatin chemotherapy is contraindicated. The approval offers a potentially more effective alternative to carboplatin-based chemotherapy for frail, elderly patients. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2017-064

    authors:

    更新日期:2017-06-01 00:00:00

  • Oncogenes Induce Replication Stress via Intragenic Replication Origins.

    abstract::Oncogenes induce premature S phase, resulting in replication-transcription conflicts and replication stress. ...

    journal_title:Cancer discovery

    pub_type: 评论,新闻

    doi:10.1158/2159-8290.CD-RW2018-039

    authors:

    更新日期:2018-04-01 00:00:00

  • Advice Offered for Sharing Research Results.

    abstract::A report from the National Academies of Sciences, Engineering, and Medicine lays out 12 recommendations to help scientists decide whether to return research results to study participants and, if they do, how to improve the sharing of information. The most important change the report recommends is harmonizing contradic...

    journal_title:Cancer discovery

    pub_type: 新闻

    doi:10.1158/2159-8290.CD-NB2018-102

    authors:

    更新日期:2018-09-01 00:00:00

  • Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer.

    abstract::In the setting of recent exciting clinical results and numerous ongoing trials, Piotrowska and colleagues explore mechanisms of acquired resistance to the mutant-specific EGFR inhibitor rociletinib, and demonstrate that loss of T790M, EGFR amplification, and small-cell transformation are all clinically relevant mechan...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-15-0616

    authors: Ichihara E,Lovly CM

    更新日期:2015-07-01 00:00:00

  • Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma.

    abstract:UNLABELLED:Adenoid cystic carcinoma (ACC), the second most common malignancy of salivary glands, is a rare tumor with a bleak prognosis for which therapeutic targets are unavailable. We used RNA sequencing (RNA-seq) to analyze low-quality RNA from archival, formaldehyde-fixed, paraffin-embedded samples. In addition to ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-15-0859

    authors: Brayer KJ,Frerich CA,Kang H,Ness SA

    更新日期:2016-02-01 00:00:00

  • Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination.

    abstract::In this issue of Cancer Discovery, Diab and colleagues demonstrate in a phase I trial enrolling 38 patients diagnosed with advanced solid tumors that combining the pegylated IL2 bempegaldesleukin with an anti-PD-1 mAb is safe, with an overall response rate of 59.5%. This compelling clinical activity is supported by th...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-20-0786

    authors: Rouanne M,Zitvogel L,Marabelle A

    更新日期:2020-08-01 00:00:00

  • Senescence Can Be BETter without the SASP?

    abstract::Global remodeling of the chromatin landscape occurs during senescence, although its functional consequence is still unclear. In this issue, Tasdemir and colleagues show that the epigenetic regulator BRD4 is required for expression of the proinflammatory senescence-associated secretory phenotype and immune clearance of...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-16-0485

    authors: Vizioli MG,Adams PD

    更新日期:2016-06-01 00:00:00

  • Evolutionary pathways in BRCA1-associated breast tumors.

    abstract::BRCA1-associated breast tumors display loss of BRCA1 and frequent somatic mutations of PTEN and TP53. Here we describe the analysis of BRCA1, PTEN, and p53 at the single cell level in 55 BRCA1-associated breast tumors and computational methods to predict the relative temporal order of somatic events, on the basis of t...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-11-0325

    authors: Martins FC,De S,Almendro V,Gönen M,Park SY,Blum JL,Herlihy W,Ethington G,Schnitt SJ,Tung N,Garber JE,Fetten K,Michor F,Polyak K

    更新日期:2012-06-01 00:00:00

  • Cryo-Electron Microscopy Reveals Architecture of the BAF Complex.

    abstract::The structure of the chromatin-remodeling BAF complex provides molecular-scale mechanistic insight. ...

    journal_title:Cancer discovery

    pub_type: 评论,杂志文章

    doi:10.1158/2159-8290.CD-RW2020-020

    authors:

    更新日期:2020-03-01 00:00:00

  • Exosome Profiling Pinpoints Cancer Type.

    abstract::A study shows that analyzing the protein contents of exosomes and related extracellular vesicles can distinguish tumors from nearby noncancerous tissue, and profiling extracellular vesicle proteins obtained from plasma may also reveal cancer type. The results support using vesicle proteins for liquid biopsies. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2020-083

    authors:

    更新日期:2020-11-01 00:00:00

  • Tiragolumab Impresses in Multiple Trials.

    abstract::The TIGIT inhibitor tiragolumab, alone or in combination with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically significant results in multiple solid malignancies-most notably non-small cell lung cancer. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-NB2020-063

    authors:

    更新日期:2020-08-01 00:00:00

  • Relapse-Driving AML Cells Exhibit Pyrimidine-Synthesis Dependency.

    abstract::Residual acute myeloid leukemia (AML) cells required bone marrow stromal cell-derived aspartate. ...

    journal_title:Cancer discovery

    pub_type: 杂志文章

    doi:10.1158/2159-8290.CD-RW2020-118

    authors:

    更新日期:2020-10-01 00:00:00